AbbVie
3Q Revenues: $7.0 billion (+9%)
3Q Earnings: $1.6 billion (+2%)
YTD Revenues: $20.5 billion (+9%)
YTD Earnings: $5.3 billion (+7%)
Comments: Humira sales were $4.7 billion in the quarter, up 16%. Imbruvica sales were $688 million, up 37%. HCV sales were down 27% to $276 million due to increased competition in the Hep-C market. Lupron sales were $201 million, up 4%. Creon sales were up 15% to $215 million. Synagis sales were up 21% to $116 million. Synthroid sales were $191 million, up 2%. AndroGel sales were down 15% to $147 million. Kaletra sales were down 38% to $85 million.